G
Galecto, Inc. (GLTO)
NCM – Real Time Price. Currency in USD
28.69
-0.22 (-0.76%)
At close: Mar 9, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
28.69
-0.22 (-0.76%)
At close: Mar 9, 2026, 4:00 PM EDT
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
| Name | Position |
|---|---|
| Dr. Becker Hewes M.D. | Chief Medical Officer |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Mr. Garrett Winslow Esq. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Sherwin Sattarzadeh | Interim Principal Executive Officer & COO |
| Mr. Ulf J. Nilsson Ph.D. | Co-Founder |
| Ms. Lori C. Firmani | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-12 | 8-K | glto-20260112.htm |
| 2026-01-06 | 8-K | glto-20251231.htm |
| 2026-01-02 | S-8 | glto-20260102.htm |
| 2025-12-16 | S-3 | d60916ds3.htm |
| 2025-12-09 | 8-K/A | glto-20251110.htm |
| 2025-11-21 | D | |
| 2025-11-10 | 8-K | d53983d8k.htm |
| 2025-11-06 | 10-Q | glto-20250930.htm |
| 2025-08-05 | 10-Q | glto-20250630.htm |
| 2025-06-20 | 8-K | glto-20250618.htm |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |